NSCLC

This study tests whether adding a precise, high-dose radiation treatment to the liver (called L-SABR) to standard immunotherapy can help people with stage IV non-small cell lung cancer that has spread to the liver. About 68 adults will be randomly assigned to receive either stand…

This study tests whether adding a cancer vaccine (OSE2101) to an immunotherapy drug (cemiplimab) can better clear tumor DNA from the blood of people with advanced lung cancer. About 160 adults with a specific immune type (HLA-A2) who have not worsened after initial treatment will…

This study tests whether adding a local treatment (like surgery or radiation) to the targeted drug brigatinib can help people with advanced ALK-positive lung cancer stay progression-free longer. About 45 participants whose cancer responds or stabilizes on brigatinib will receive …

This study is for people with advanced non-small cell lung cancer (stage IIIB/C-IV) who cannot tolerate standard chemoradiation. It tests a sequence of platinum-based chemotherapy, followed by a special type of radiation (hypofractionated radiotherapy), and then the immunotherapy…

This early-phase study tests a new drug called SLV-154 in about 70 people whose solid tumors (like head and neck, lung, breast, or ovarian cancer) have spread. The main goal is to find a safe dose and watch for side effects. Participants must have a confirmed diagnosis and be in …

This study tests whether using a tool called OncoChoice to select chemotherapy can help shrink tumors or slow their growth in people with advanced non-small cell lung cancer (NSCLC) that has spread. About 29 adults who have already tried at least one prior treatment will receive …

This study tests a new drug called HLX37 in people with advanced or metastatic solid tumors (cancers that have spread). The drug is a bispecific antibody that targets two proteins (PD-L1 and VEGF) involved in tumor growth. The main goals are to check the drug's safety, find the r…

This study tests a new combination of drugs (RAS(ON) inhibitors plus ivonescimab) in adults with advanced or metastatic solid tumors that have a RAS mutation. The goal is to see if the combination is safe and can shrink tumors or slow their growth. About 370 people with cancers l…

This study tests a new drug called TNG462, given with other cancer medicines, for people with pancreatic or lung cancer that has a specific genetic change (MTAP loss). The goal is to find safe doses and see if the combination shrinks tumors. About 183 adults with advanced cancer …

This study tests an experimental oral drug called Alintegimod combined with standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if the com…

This study tests a new drug called PC14586 (rezatapopt) in people with advanced or spreading solid tumors that have a specific change in the TP53 gene (Y220C mutation). The goal is to see if the drug is safe and works against these cancers. About 300 adults (and some teens after …

This study is for adults aged 70 or older, or those who are frail, with advanced non-small cell lung cancer that has a low PD-L1 score. The goal is to see if using a reduced dose of chemotherapy together with an immunotherapy drug (anti-PD-1) causes fewer side effects that force …

This study tests a new drug called EIK1001 added to standard immunotherapy (pembrolizumab) and chemotherapy for people with stage 4 non-small cell lung cancer who haven't had treatment yet. About 70 participants will be enrolled to see if the combination is safe and shrinks tumor…

This study tests an experimental drug called YL202 in about 200 people with advanced solid tumors, including lung, breast, and head & neck cancers. The goal is to see if the drug can shrink tumors and how safe it is. Participants must be between 18 and 75 years old and have tried…

This study tests whether adding a drug called narlumosbart and precise radiation (SBRT) to standard chemotherapy and immunotherapy can help people with advanced lung cancer that has spread to the bones. The drug and radiation are meant to improve the immune system's ability to fi…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This early-phase study tests a new drug called IDE161, alone or with another drug (pembrolizumab), in people with advanced solid tumors (like breast, ovarian, prostate, or lung cancer) that have not responded to other treatments. The main goals are to check safety, find the right…

This study tests a new drug called HC010 in 50 people with advanced non-small cell lung cancer that has a specific marker (PD-L1 positive). The goal is to see if the drug can shrink tumors and how safe it is. Participants receive HC010 as their first treatment, and researchers wi…

This study looks at how well a drug called sugemalimab works when combined with standard chemotherapy as the first treatment for people with advanced non-small cell lung cancer (NSCLC). The study is happening in real-world clinics, not just research hospitals, and includes 150 ad…

This study tests a new drug, TUB-030, in adults with advanced solid tumors like head and neck, lung, breast, and colorectal cancers. The main goals are to find a safe dose and see if the drug can shrink tumors. Participants receive the drug every 3 weeks and are closely monitored…

This study tests a new type of CAR T cell therapy for adults with advanced solid tumors (like colorectal, lung, or pancreatic cancer) that have lost a specific marker on their cells. The treatment uses the patient's own immune cells, modified to target cancer cells while protecti…

This early-stage study tests a new drug called RMC-5127 in adults with advanced solid tumors that have a specific KRAS G12V gene change. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 574 people with lung, colorectal, or panc…

This study tests a combination of two immune-boosting drugs (iparomlimab and tuvonralimab) plus chemotherapy for people with stage III non-small cell lung cancer that cannot be surgically removed. The goal is to see if this treatment shrinks tumors enough to allow surgery or impr…

This early-phase study tests a new treatment called NK510 (a type of immune cell therapy) combined with PD-1 inhibitors for people with advanced non-small cell lung cancer that has come back or not responded to prior treatments. The trial includes two ways to give the therapy: th…

This early-phase study tests a new drug (ORIC-114) combined with an existing targeted therapy (amivantamab) in about 76 people with advanced lung cancer that has a specific genetic change (EGFR exon20 insertion). The goal is to find the safest dose and see if the combination can …

This study tests whether combining a targeted drug (adagrasib) with precise radiation (SRS) can better control brain metastases in people with a specific type of lung cancer (KRAS G12C-mutated NSCLC). About 30 adults with untreated brain tumors will receive both treatments. The m…

This study tests whether adding the drug MK-2870 to standard pembrolizumab after initial chemo-immunotherapy helps people with advanced squamous non-small cell lung cancer live longer. About 851 participants will receive pembrolizumab plus chemotherapy, then either continue pembr…

This study compares two treatments given before surgery for stage II-IIIA non-small cell lung cancer: immunotherapy (toripalimab) plus radiation versus immunotherapy plus chemotherapy. The goal is to see which combination works better at shrinking tumors and improving surgery out…

This study tests whether adding the drug sintilimab to standard chemotherapy and a personalized radiation plan can help control stage III non-small cell lung cancer. About 35 adults aged 18-75 who cannot have surgery will receive the combination. The main goal is to see how long …

This study tests a new treatment for people with a certain type of lung cancer (stage II to IIIB) who had surgery but still had cancer cells left after standard chemo and immunotherapy. The treatment combines a special immune cell therapy (L-TIL) with another immunotherapy drug (…

This study tests whether adding a special surgical glue (Progel Platinum) to the standard stapling method during lung cancer surgery can help patients recover faster. About 160 adults having keyhole surgery for non-small cell lung cancer will take part. The main goal is to see if…

This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166…

This study tests a drug called repotrectinib in 20 people with a specific type of lung cancer (ROS1-positive) that has spread to the brain. The goal is to see if the drug can shrink or control brain tumors. Participants take the drug by mouth, and doctors monitor safety and how w…

This early-stage study tests a new drug called TORL-1-23 in people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. About 90 participants will take part.

This study is testing a new drug, enzelkitug, for people with advanced solid tumors that have spread or cannot be removed by surgery. The trial includes many cancer types like lung, head and neck, melanoma, breast, and others. The main goal is to check the drug's safety and find …

This early-phase study tests a new drug called PRTH-101, alone or with an approved immunotherapy (pembrolizumab), in adults with advanced or metastatic solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if …

This study looks at whether people with lung cancer that has spread to the brain can safely delay radiation therapy if they take the targeted drug alectinib. It involves 56 adults with specific genetic changes. The goal is to see if alectinib alone controls brain tumors as well a…

This early-phase study tests an oral drug called S241656 in adults with advanced cancers that have certain gene changes (KRAS, BRAF, and others). The drug is given alone or with other cancer treatments. The goal is to find safe doses and see if the drug shrinks tumors. About 554 …

This study is for people with stage III non-small cell lung cancer that cannot be removed by surgery. Researchers want to see if adding another immunotherapy drug (tremelimumab) and extra chemotherapy to the standard drug (durvalumab) can lower the amount of cancer DNA found in t…

This study tests a new oral drug, RMC-6236, against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that has a specific RAS mutation and has already been treated with immunotherapy and platinum chemo. About 420 adults will be randomly assigned…

This study tests a new drug called JAB-8263 in adults with advanced solid tumors (like lung or ovarian cancer) or blood cancers (like leukemia) that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 15…

This study tests a new drug called EP0031 in about 265 adults with advanced cancers (like non-small cell lung cancer) that have a specific RET gene change. The goal is to see if the drug is safe, what side effects it causes, and how well it shrinks tumors. Participants must have …

This study tests an experimental drug called STX-721 in people with advanced non-small cell lung cancer that has specific gene changes (EGFR or HER2 exon 20 insertions). The goal is to find a safe dose and see if the drug shrinks tumors. About 251 participants will receive the dr…

This early-stage study tests an experimental oral drug, NST-628, in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. About 230 participants w…

This early-phase study tests a new drug called NRM-823, alone or with an immunotherapy, in 150 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. The study includes several cancer types lik…

This study is for people with a common type of advanced lung cancer (non-small cell) that has stopped responding to current targeted pills. The trial will test a two-step approach: first, standard chemotherapy, then a newer targeted drug called befotertinib. The goal is to see if…

This early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors (including some lung cancers) that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants …

This early-phase study tests a new drug called BBO-11818 in adults with advanced lung, pancreatic, or colorectal cancers that have a KRAS mutation. The main goals are to check safety and find the best dose, while also seeing if the drug can shrink tumors. About 387 participants w…

This study tests whether two immunotherapy drugs (cemiplimab and fianlimab) given before radiation can shrink tumors in people with locally advanced non-small cell lung cancer who cannot have surgery. About 76 participants will receive three cycles of the drug combination, then r…

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This study tests a new drug that delivers radiation directly to cancer cells with a specific marker (GRPR). It is for adults with advanced cancers like prostate, breast, lung, or colon cancer that have come back or spread. The main goal is to find a safe dose and check for side e…

This study tests a new drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The goal is to find a safe dose and see if the drug can shrink tumors. About 231 participants will take part in two phases: first to check sa…

This study tests an experimental drug called VT3989, taken daily by mouth, in people with advanced solid tumors, mesothelioma, or non-small cell lung cancer that has stopped responding to standard treatments. The main goals are to check the drug's safety and side effects, and to …

This early-stage study tests a new drug called BBO-8520 in about 350 adults with advanced non-small cell lung cancer that has a specific genetic change (KRAS G12C). The main goals are to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participa…

This study tests whether adding BIO 300 to standard chest radiation can prevent severe lung inflammation (pneumonitis) in people with early-stage non-small cell lung cancer who also have interstitial lung disease (lung scarring). About 25 adults will receive the combination and b…

This study is testing a new blood test called TheraSure CNI-Monitor for people with advanced lung cancer (NSCLC) who are receiving immunotherapy. The test looks for tiny bits of tumor DNA in the blood to see if the cancer is responding to treatment. Researchers want to know if th…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps immune cells attack…

This study looks at two radiation treatments for people with 4 to 15 brain tumors that have spread from other cancers. One treatment is CyberKnife radiosurgery, which delivers high-dose radiation in 1 or 2 sessions. The other is whole-brain radiotherapy, which requires 10 session…

This study tests whether using a breathing machine (CPAP or BiPAP) can reduce tumor movement during radiation therapy for people with advanced lung cancer, esophageal cancer, or lymphoma. The goal is to see if these devices help keep the tumor still, which could make treatment mo…

This study looks at whether a special intermittent fasting diet can help people with advanced lung cancer who are receiving immunotherapy. Researchers want to see if the diet is safe and if it can make the cancer treatment work better. About 66 patients will take part, following …

This study looks at people with early-stage lung cancer who had surgery and have no detectable tumor DNA in their blood. Half will get standard follow-up care, and the other half will have regular DNA tests and imaging instead of immediate extra treatment. The goal is to see if t…

This study looks at whether chest CT scans can help predict how well lung cancer responds to chemoimmunotherapy given before surgery. Researchers will compare scan images with actual tumor response after surgery in 150 adults with resectable non-small cell lung cancer. The goal i…

This observational study collects tumor tissue and blood cells from 200 adults with advanced solid tumors like colorectal, lung, or pancreatic cancer. The goal is to understand how often tumors lose a specific marker (HLA) and to store participants' own T cells for possible futur…

This study watches 100 adults with a certain type of advanced lung cancer who are already receiving a drug combo (amivantamab plus chemo) through an early access program. Researchers want to see how long the treatment keeps the cancer from growing in everyday medical practice. No…

This study is for adults with non-small cell lung cancer (NSCLC) who are about to start immunotherapy. Researchers want to understand how the body makes antibodies against the immunotherapy drugs themselves. By analyzing blood samples from 270 participants, they hope to learn mor…

This study is testing whether a special PET scan can predict how well a targeted cancer drug works in people with advanced lung cancer. About 50 adults with metastatic non-small cell lung cancer will get the scan before and during treatment. The goal is to see if changes in the s…

This study aims to uncover the molecular differences between the original lung tumor and cancer that has spread to other parts of the body. Researchers will analyze DNA from stored tumor samples of 25 adults with non-small cell lung cancer who are healthy enough for surgery. The …

This study is building a computer model to predict how well pre-surgery treatment works for people with non-small cell lung cancer. Researchers will collect data from 500 participants to see if the model can accurately forecast treatment results. The goal is to help doctors make …

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already scheduled to receive immunotherapy (PD-1/PD-L1 inhibitors). Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if chan…